Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review

Head and Neck Cancer

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial

Lancet Oncol

Ma D, Price K, Moore E, Patel S, Hinni M, Routman D, Fruth B, Foster N, Van Abel K, Yin L, Neben-Wittich M, Garces Y, McGee L, Lester S, Rwigema JC, Holtzman A, Price D, Janus J, Kasperbauer J, Chintakuntlawar A, Garcia J, Foote R

doi: 10.1016/S1470-2045(25)00324-9

Head and Neck Cancer

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Exp Hematol Oncol

Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N

doi: 10.1186/s40164-025-00703-x

Breast Cancer

Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials

Cancer Treat Rev

Kirmani N, De León-Fernández N, Rodriguez-Parra JD, Ghanem L, Hakkeem B, Briceño-Morales C, Briceño-Morales X

doi: 10.1016/j.ctrv.2026.103093

Genitourinary Cancer

Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review

Cancer Treat Rev

Charnley N, Fife K, Heng DYC, Larkin J, McGrane J, Négrier S, Vasudev N, Venugopal B, Chisholm A, Ogareva A, Prendergast Á, Albiges L

doi: 10.1016/j.ctrv.2025.103024

Skin Cancer

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

Eur J Cancer

Robert C, Gérard E, Lanoy E, Quéreux G, Bernard P, Viguier M, Grange F, Meyer N, Dinulescu M, Legoupil D, Neidhardt EM, Saiag P, Trabelsi S, Célérier P, Nardin C, Maubec E, Duval-Modeste AB, Hainaut E, Darras S, Maillard H, Guegan S, Arnault JP, Stoebner PE, LE Corre Y, Peuvrel L, Bonniaud B, Herrscher H, Granel-Brocard F, Vataire AL, Tabellion A, Lebbé C, Mortier L

doi: 10.1016/j.ejca.2026.116596

Genitourinary Cancer

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

Lancet Oncol

Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P

doi: 10.1016/S1470-2045(25)00658-8

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Genitourinary Cancer

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

JAMA Oncol

Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L

doi: 10.1001/jamaoncol.2025.1891

Gastrointestinal Cancer

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial

Int J Cancer

Han W, Gao L, Wang X, Li C, Zhou Z, Deng L, Wang W, Liu W, Wang X, Chen D, Feng Q, Bi N, Zhang T, Wang J, Zhai Y, Zhao Y, Xiao Z, Jing‐Jin‐Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG)

doi: 10.1002/ijc.70176

Related content

De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial

Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial

Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials

Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review

Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal squamous cell carcinoma: A multicenter, open-label, randomized, phase III clinical trial